Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1965 1
1989 2
1990 1
1992 5
1993 4
1994 3
1995 1
1997 1
2009 3
2010 2
2011 2
2012 1
2013 1
2014 1
2015 1
2016 1
2017 1
2021 3
2022 2
2023 2
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Pirfenidone in idiopathic pulmonary fibrosis.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8. Eur Respir J. 2010. PMID: 19996196 Free article. Clinical Trial.
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Furuhashi K, Yagi A, Saiki H, Yasuma T, Okano T, Tomaru A, Tanigawa M, Yoshida M, Hataji O, Ibata H, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T. Nishimura T, et al. Among authors: ibata h. Cancer Med. 2024 Apr;13(8):e7188. doi: 10.1002/cam4.7188. Cancer Med. 2024. PMID: 38629295 Free PMC article.
Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis.
Sakaue S, Yamaguchi E, Inoue Y, Takahashi M, Hirata J, Suzuki K, Ito S, Arai T, Hirose M, Tanino Y, Nikaido T, Ichiwata T, Ohkouchi S, Hirano T, Takada T, Miyawaki S, Dofuku S, Maeda Y, Nii T, Kishikawa T, Ogawa K, Masuda T, Yamamoto K, Sonehara K, Tazawa R, Morimoto K, Takaki M, Konno S, Suzuki M, Tomii K, Nakagawa A, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Watanabe M, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Ibata H, Hizawa N, Mochizuki H, Kumanogoh A, Matsuda F, Nakata K, Hirota T, Tamari M, Okada Y. Sakaue S, et al. Among authors: ibata h. Nat Commun. 2021 Feb 15;12(1):1032. doi: 10.1038/s41467-021-21011-y. Nat Commun. 2021. PMID: 33589587 Free PMC article.
Bronchopulmonary disease in ulcerative colitis.
Gabazza EC, Taguchi O, Yamakami T, Machishi M, Ibata H, Fukukita S, Tsutsui K, Imoto I, Suzuki S, Kitagawa T, et al. Gabazza EC, et al. Among authors: ibata h. Intern Med. 1992 Sep;31(9):1155-9. doi: 10.2169/internalmedicine.31.1155. Intern Med. 1992. PMID: 1421730 Free article.
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy.
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Yagi A, D'Alessandro VF, Yasuma T, Furuhashi K, Saiki H, Okano T, Tomaru A, Tanigawa M, D'Alessandro-Gabazza CN, Gabazza EC, Yoshida M, Hataji O, Ibata H, Kobayashi T. Nishimura T, et al. Among authors: ibata h. Cancers (Basel). 2022 Aug 16;14(16):3953. doi: 10.3390/cancers14163953. Cancers (Basel). 2022. PMID: 36010946 Free PMC article.
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Cohen AT, et al. N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096. N Engl J Med. 2013. PMID: 23388003 Free article. Clinical Trial.
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
Nishimura T, Fujimoto H, Okano T, Naito M, Tsuji C, Iwanaka S, Sakakura Y, Yasuma T, D'Alessandro-Gabazza CN, Oomoto Y, Gabazza EC, Kobayashi T, Ibata H. Nishimura T, et al. Among authors: ibata h. Cancers (Basel). 2022 Jun 16;14(12):2970. doi: 10.3390/cancers14122970. Cancers (Basel). 2022. PMID: 35740634 Free PMC article.
Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.
Nishimura T, Fujiwara T, Fujimoto H, Tarumi H, Tsuji C, Iwanaka S, Sakakura Y, Naito M, Okugawa Y, Yasuma T, Gabazza EC, Oomoto Y, Kobayashi T, Ibata H. Nishimura T, et al. Among authors: ibata h. Thorac Cancer. 2023 Mar;14(7):709-713. doi: 10.1111/1759-7714.14807. Epub 2023 Jan 29. Thorac Cancer. 2023. PMID: 36710365 Free PMC article.
42 results